Ares Capital Corp
XHAM:9A2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ares Capital Corp
XHAM:9A2
|
US |
|
C
|
Cleveland-Cliffs Inc
XMUN:CVA
|
US |
|
Trevi Therapeutics Inc
NASDAQ:TRVI
|
US |
|
Auri Inc
OTC:AURI
|
US |
|
Anglogold Ashanti PLC
F:HT3
|
US |
|
B
|
BioMarin Pharmaceutical Inc
XMUN:BM8
|
US |
Intrinsic Value
Is 9A2 undervalued or overvalued?
See the intrinsic value estimate for 
Ares Capital Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
9A2 looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 9A2’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Ares Capital Does
Ares Capital Corp. is a business development company that lends money and sometimes takes equity stakes in middle-market companies, usually private businesses that are too large for small-bank lending but not big enough to tap the public bond market easily. It focuses on senior secured loans, subordinated debt, and other forms of private credit, often to companies backed by private equity sponsors.
- Headquarters
- United States of America US
- Employees
- 4 250
- IPO date
- Oct 8, 2012
Ares Capital has no economic moat
Borrowers can seek comparable loans from competing banks and private lenders, leaving Ares Capital under pressure to match their prices and terms. Its relationships and lending experience help it win business, but do not prevent rivals from competing for the same borrowers.
Read the full moat analysis
Revenue & Expenses Breakdown
Ares Capital Corp
Earnings Waterfall
Ares Capital Corp
The intrinsic value for Ares Capital Corp (9A2) under the Base Case is hidden EUR.
Compared with the current market price of 16.49 EUR, the stock appears hidden.